Procedures
bleeding, hand‐foot skin reaction, toxicity, abnormal liver function, proteinuria, Depression, Cancer
ADVERSE EVENT, BLEEDING, DISEASE PROGRESSION, ADVERSE EVENTS, HYPERTENSION, CANCER
All included patients underwent GA and G8 screening tool before treatment. GA included Instrumental (IADL) and Activities in Daily Living (ADL) questionnaires, the Mini‐Nutritional Assessment (MNA), the Geriatric Depression Scale‐15 (GDS‐15), the Mini‐Mental State Examination (MMSE), the Cumulative Illness Rating Scale‐Geriatric (CIRS‐G) and Timed Up and Go (TUG) test.Fruquintinib was administered orally on 21 consecutive days in a 28‐day treatment cycle. All patients underwent dose escalation during the first cycle of fruquintinib treatment. The initial week involved oral administration of fruquintinib at a dosage of 3 mg/day. If this dosage was well tolerated, the dosage was increased to 4 mg/day during the second week. Subsequently, if the patient still exhibited tolerability, the dosage was further escalated to 5 mg/day during the third week. From the second cycle, patients were given the maximum dose that they had tolerated in the first cycle. CT scans were performed every two cycles for efficacy evaluation.AEs were recorded following the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Adjustments to the fruquintinib dosage were made during treatment based on the occurrence of adverse events. If patients exhibited hand‐foot skin reaction, proteinuria, hypertension, decreased platelet count, bleeding, or abnormal liver function, dose modifications were implemented according to previously established criteria.Criteria for patient withdrawal from the trial were as follows: (1) disease progression according to the (RECIST) 1.1 standard; (2) occurrence of unacceptable toxicity; (3) patient's request to withdraw from the trial; and (4) delay of more than 2 weeks in patient's treatment.